Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

A compound of formula (I):

• in which:
• Y at each occurrence is independently selected from N and CH;
• Y1 is CR5;
• wherein R5 is selected from hydrogen, methoxy and imidazolyl;
• wherein said imidazolyl is unsubstituted or substituted with methyl;
• R1 is pyridinyl unsubstituted or substituted with 1 to 3 R6 groups;
• R2 is selected from hydrogen, halo, hydroxy, C1-4alkyl, C1-4alkoxy, methoxy-carbonyl, 3,6-dihydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl-oxy and cyclobutyl;
• wherein said C1-4alkyl, C1-4alkoxy, cyclobutyl or tetrahydro-2H-pyran-4-yl of R2 can be unsubstituted or substituted with 1 to 3 groups independently selected from halo, hydroxy, cyano, C1-4alkoxy, morpholino, piperazinyl and NR5aR5b;
• wherein R5a is selected from hydrogen and C1-4alkyl;
• and R5b is selected from hydroxy-ethyl;
• wherein said piperazinyl substituent of R2 can be unsubstituted or further substituted with C1-4alkyl;
• R3 is selected from hydrogen and halo;
• R4 is selected from —SF5 and —Y2—CF2—Y3;
• R6 at each occurrence is independently selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkoxy, cyano, trifluoromethyl, halo, amino, methyl-carbonyl, methoxy-carbonyl, cyclopropyl and pyrrolidinyl-methyl;
• wherein said C1-4alkyl or C1-4alkoxy of R6 is unsubstituted or substituted with 1 to 3 groups independently selected from halo and hydroxy;
• Y2 is selected from CF2, O and S(O)0-2;
• and
• Y3 is selected from hydrogen, halo, methyl, difluoromethyl and trifluoromethyl;
• Y4 is CR2;
• Y5 and Y6 are independently CR5;
• wherein R5 is selected from hydrogen and halo;
• or the pharmaceutically acceptable salts thereof;
• with the proviso that the compounds of formula I do not include 3-(2-aminoquinazolin-6-yl)-4-methyl-N-(4-(trifluoromethoxy)phenyl)-benzamide and 3-(2-aminoquinazolin-6-yl)-5-bromo-N-(4-(trifluoromethoxy)phenyl)-benzamide.